286 related articles for article (PubMed ID: 9266782)
1. A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: The Flolan International Randomized Survival Trial (FIRST).
Califf RM; Adams KF; McKenna WJ; Gheorghiade M; Uretsky BF; McNulty SE; Darius H; Schulman K; Zannad F; Handberg-Thurmond E; Harrell FE; Wheeler W; Soler-Soler J; Swedberg K
Am Heart J; 1997 Jul; 134(1):44-54. PubMed ID: 9266782
[TBL] [Abstract][Full Text] [Related]
2. Bridging to heart transplantation: prostaglandin E1 versus prostacyclin versus dobutamine.
Stanek B; Sturm B; Frey B; Hülsmann M; Bojic A; Berger R; Rödler S; Locker G; Grimm M; Laufer G; Pacher R
J Heart Lung Transplant; 1999 Apr; 18(4):358-66. PubMed ID: 10226901
[TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of epoprostenol in patients with severe congestive heart failure. Epoprostenol Multicenter Research Group.
Sueta CA; Gheorghiade M; Adams KF; Bourge RC; Murali S; Uretsky BF; Pritzker MR; McGoon MD; Butman SM; Grossman SH
Am J Cardiol; 1995 Jan; 75(3):34A-43A. PubMed ID: 7840053
[TBL] [Abstract][Full Text] [Related]
4. Hemodynamics as surrogate end points for survival in advanced heart failure: an analysis from FIRST.
Shah MR; Stinnett SS; McNulty SE; Gheorghiade M; Zannad F; Uretsky B; Adams KF; Califf RM; O'connor CM
Am Heart J; 2001 Jun; 141(6):908-14. PubMed ID: 11376303
[TBL] [Abstract][Full Text] [Related]
5. Effects of increased dose of diuretics on symptoms, weight, 6-minute walk distance, and echocardiographic measurements of left ventricular systolic and diastolic function in 51 patients with symptomatic heart failure caused by reduced left ventricular ejection fraction treated with beta blockers and angiotensin-converting enzyme inhibitors or angiotensin receptor blockers.
Kumar A; Aronow WS; Vadnerkar A; Sivan K; Mittal S
Am J Ther; 2009; 16(1):5-7. PubMed ID: 19142162
[TBL] [Abstract][Full Text] [Related]
6. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial.
Badesch DB; Tapson VF; McGoon MD; Brundage BH; Rubin LJ; Wigley FM; Rich S; Barst RJ; Barrett PS; Kral KM; Jöbsis MM; Loyd JE; Murali S; Frost A; Girgis R; Bourge RC; Ralph DD; Elliott CG; Hill NS; Langleben D; Schilz RJ; McLaughlin VV; Robbins IM; Groves BM; Shapiro S; Medsger TA
Ann Intern Med; 2000 Mar; 132(6):425-34. PubMed ID: 10733441
[TBL] [Abstract][Full Text] [Related]
7. A randomized crossover trial of levodopa in congestive heart failure.
Leszek P; Zieliński T; Janas J; Brodzki M; Klimkiewicz H; Korewicki J
J Card Fail; 1996 Sep; 2(3):163-74; discussion 175-6. PubMed ID: 8891854
[TBL] [Abstract][Full Text] [Related]
8. Can further benefit be achieved by adding flosequinan to patients with congestive heart failure who remain symptomatic on diuretic, digoxin, and an angiotensin converting enzyme inhibitor? Results of the flosequinan-ACE inhibitor trial (FACET).
Massie BM; Berk MR; Brozena SC; Elkayam U; Plehn JF; Kukin ML; Packer M; Murphy BE; Neuberg GW; Steingart RM
Circulation; 1993 Aug; 88(2):492-501. PubMed ID: 8339411
[TBL] [Abstract][Full Text] [Related]
9. Effects of increasing maintenance dose of digoxin on left ventricular function and neurohormones in patients with chronic heart failure treated with diuretics and angiotensin-converting enzyme inhibitors.
Gheorghiade M; Hall VB; Jacobsen G; Alam M; Rosman H; Goldstein S
Circulation; 1995 Oct; 92(7):1801-7. PubMed ID: 7671364
[TBL] [Abstract][Full Text] [Related]
10. Effects of prostacyclin on the pulmonary vascular tone and cardiac contractility of patients with pulmonary hypertension secondary to end-stage heart failure.
Montalescot G; Drobinski G; Meurin P; Maclouf J; Sotirov I; Philippe F; Choussat R; Morin E; Thomas D
Am J Cardiol; 1998 Sep; 82(6):749-55. PubMed ID: 9761085
[TBL] [Abstract][Full Text] [Related]
11. Rationale and design of the third vasodilator-heart failure trial (V-HeFT III): felodipine as adjunctive therapy to enalapril and loop diuretics with or without digoxin in chronic congestive heart failure. V-HeFT III investigators.
Boden WE; Ziesche S; Carson PE; Conrad CH; Syat D; Cohn JN
Am J Cardiol; 1996 May; 77(12):1078-82. PubMed ID: 8644661
[TBL] [Abstract][Full Text] [Related]
12. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival.
Sitbon O; Humbert M; Nunes H; Parent F; Garcia G; Hervé P; Rainisio M; Simonneau G
J Am Coll Cardiol; 2002 Aug; 40(4):780-8. PubMed ID: 12204511
[TBL] [Abstract][Full Text] [Related]
13. Effects of digoxin on morbidity and mortality in diastolic heart failure: the ancillary digitalis investigation group trial.
Ahmed A; Rich MW; Fleg JL; Zile MR; Young JB; Kitzman DW; Love TE; Aronow WS; Adams KF; Gheorghiade M
Circulation; 2006 Aug; 114(5):397-403. PubMed ID: 16864724
[TBL] [Abstract][Full Text] [Related]
14. A comparison of prostacyclin and sodium nitroprusside for the treatment of heart failure after cardiac surgery.
Kieler-Jensen N; Houltz E; Ricksten SE
J Cardiothorac Vasc Anesth; 1995 Dec; 9(6):641-6. PubMed ID: 8664453
[TBL] [Abstract][Full Text] [Related]
15. Beta blockade in congestive heart failure: persistent adverse haemodynamic effects during chronic treatment with subsequent doses.
Kukin ML; Kalman J; Mannino MM; Buchholz-Varley C; Ocampo O
Heart; 1997 Nov; 78(5):444-9. PubMed ID: 9415001
[TBL] [Abstract][Full Text] [Related]
16. Clinical and neurohormonal effects of nicardipine hydrochloride in patients with severe chronic heart failure receiving angiotensin-converting enzyme inhibitor therapy.
Benatar D; Hall V; Reddy S; Gheorghiade M
Am J Ther; 1998 Jan; 5(1):25-32. PubMed ID: 10099034
[TBL] [Abstract][Full Text] [Related]
17. Sustained hemodynamic and clinical effects of a new cardiotonic agent, WIN 47203, in patients with severe congestive heart failure.
Maskin CS; Sinoway L; Chadwick B; Sonnenblick EH; Le Jemtel TH
Circulation; 1983 May; 67(5):1065-70. PubMed ID: 6831672
[TBL] [Abstract][Full Text] [Related]
18. The effects of enalapril-digoxin-diuretic combination therapy on nutritional and anthropometric indices in chronic congestive heart failure: preliminary findings in cardiac cachexia.
Adigun AQ; Ajayi AA
Eur J Heart Fail; 2001 Jun; 3(3):359-63. PubMed ID: 11378008
[TBL] [Abstract][Full Text] [Related]
19. [The main aspects of symptomatic therapy of chronic heart failure].
Zaliaduonyte-Peksiene D; Mikuckaite L; Kavoliūniene A
Medicina (Kaunas); 2006; 42(11):949-55. PubMed ID: 17172798
[TBL] [Abstract][Full Text] [Related]
20. Predictors of decreased renal function in patients with heart failure during angiotensin-converting enzyme inhibitor therapy: results from the studies of left ventricular dysfunction (SOLVD).
Knight EL; Glynn RJ; McIntyre KM; Mogun H; Avorn J
Am Heart J; 1999 Nov; 138(5 Pt 1):849-55. PubMed ID: 10539815
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
